We are live on ! Find out more
NLSPW

NLS Pharmaceutics Warrant
NLSPW

Delisted

NLSPW was delisted on the 30th of October, 2025.

Back to rankings

6 hedge funds and large institutions have $874K invested in NLS Pharmaceutics Warrant in 2021 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

20% more funds holding

Funds holding: 5 → 6 (+1)

1% less capital invested

Capital invested by funds: $886K → $874K (-$12K)

Holders
6
Holders Change
+1
Holders Change %
+20%
% of All Funds
0.1%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
2
Reduced
–
Closed
–
Calls
$872K
Puts
–
Net Calls
+$872K
Net Calls Change
+$872K

Top Buyers

Rank Fund Capital Flow
1
Bank Julius Baer & Co
Bank Julius Baer & Co
Switzerland
+$6.46K
2
WAM
Warberg Asset Management
Illinois
+$4.53K
3
UBS Group
UBS Group
Switzerland
+$201

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
AC
1
Armistice Capital
New York
$452K – – –
Hudson Bay Capital Management
2
Hudson Bay Capital Management
Connecticut
$192K – – –
WVP
3
Worth Venture Partners
New Jersey
$176K – – –
WAM
4
Warberg Asset Management
Illinois
$44K +$4.53K +5,111 +15%
Bank Julius Baer & Co
5
Bank Julius Baer & Co
Switzerland
$7K +$6.46K +7,292 New
UBS Group
6
UBS Group
Switzerland
$3K +$201 +227 +7%

NLSPW Hedge Fund Activity: Q2 2021 in Review

6 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in NLS Pharmaceutics Warrant (NLSPW) for Q2 2021, worth a combined $874K — down 1.4% from $886K a quarter earlier.

Buyers outnumbered sellers: 1 fund opened new NLSPW positions and 0 closed out — a net gain of 1 holder — while 2 added to existing stakes and 0 trimmed.

The largest buyer was Bank Julius Baer & Co, opening a new position worth an estimated $6.46K.

  • 6 institutional investors held NLS Pharmaceutics Warrant (NLSPW) as of Q2 2021, up from 5 in Q1 2021.
  • Funds reported $874K of NLS Pharmaceutics Warrant stock for Q2 2021, down 1.4% quarter-over-quarter.
  • 1 fund opened new NLS Pharmaceutics Warrant positions in Q2 2021 and 0 closed out, a net change of +1 holder.
  • The largest NLS Pharmaceutics Warrant buyer in Q2 2021 was Bank Julius Baer & Co, an estimated $6.46K added.

Based on aggregated 13F filings for Q2 2021.